Study Highlights Promising New Treatment Option for Patients With Treatment-Resistant Acute Myeloid Leukemia
Study Highlights Promising New Treatment Option for Patients With Treatment-Resistant Acute Myeloid Leukemia
Details
More Products & Services
People
Kimberly Sweeney
Roswell Park Comprehensive Cancer Center
Vice President of Patient Experience
Sai Yendamuri
Roswell Park Comprehensive Cancer Center
Chief Strategy Officer; SVP of Business Development & Outreach; Chair of Thoracic Surgery
Shashi Lele
Roswell Park Comprehensive Cancer Center
Medical Director, International Patients
Sunita Panesar
Roswell Park Comprehensive Cancer Center
Vice President of Strategy, Business Development & Outreach
Description
HIGHLIGHTS:
- Ziftomenib could be next targeted therapy approved to treat AML
- FDA recognized drug as a ‘breakthrough therapy’ earlier this year
- Results especially promising in patients with high-risk leukemia subtypes
- Ziftomenib could be next targeted therapy approved to treat AML
- FDA recognized drug as a ‘breakthrough therapy’ earlier this year
- Results especially promising in patients with high-risk leukemia subtypes
Share
Recent Chats
Share via email
Future: handle WhatsApp here
Future: handle LinkedIn here
Future: handle Twitter here
SUBMENU HERE
Share via Chat
Copy Link